Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6Neoplasms 3Neoplasm Metastasis 3Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 2Glioblastoma 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hamartoma Syndrome, Multiple 1Gliosarcoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Breast Diseases 1Brain Neoplasms 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

Nivolumab 2pembrolizumab 1pazopanib 1elacestrant 1dactolisib 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1RAD1901 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Injections 1Ifosfamide 1Doxorubicin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Perivascular Epithelioid Cell Neoplasms × dactolisib × Clear all
NCT01690871 2013-08-02

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Novartis

Phase 2 Withdrawn

Tuberous Sclerosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡